Finally, it has been shown in chemotherapy-resistant triple negative breast cancers that MYC and myeloid cell leukemia-1 (MCL1) genes are overexpressed, therefore promoting an OXPHOS metabolism [85]. This evidence concerns the gene MCL1 and triple-negative breast carcinoma.